Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Adverum Biotechnologies Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ADVM
Nasdaq
8731
https://adverum.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Adverum Biotechnologies Inc
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
- Mar 27th, 2024 1:35 pm
Adverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial Adjustments
- Mar 20th, 2024 9:33 am
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
- Mar 19th, 2024 1:40 pm
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
- Mar 18th, 2024 8:05 pm
Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop
- Mar 6th, 2024 8:07 pm
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
- Feb 28th, 2024 9:05 pm
Stocks on the Launchpad: The Next 3 Market Sensations
- Feb 27th, 2024 11:10 am
Unleash Massive Returns With These 3 Top Penny Stocks
- Feb 22nd, 2024 11:15 am
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 12th, 2024 1:00 pm
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
- Feb 8th, 2024 12:00 pm
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
- Feb 5th, 2024 12:45 pm
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
- Feb 1st, 2024 10:30 pm
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
- Jan 29th, 2024 1:00 pm
Here's Why You Should Invest in Adverum (ADVM) Stock Now
- Jan 4th, 2024 1:27 pm
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
- Dec 7th, 2023 9:05 pm
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
- Nov 28th, 2023 9:05 pm
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
- Nov 9th, 2023 9:05 pm
Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors
- Nov 6th, 2023 1:00 pm
Adverum Biotechnologies Announces 3-Year Efficacy and Safety ResultsĀ from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
- Nov 4th, 2023 9:54 pm
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
- Oct 24th, 2023 4:30 pm
Scroll